Given that heterozygous loss of TSC1 is common in renal cell carcinoma (>30%) [23], TSC1 and TSC2 may be screened as predictive biomarkers of everolimus in renal cell carcinoma patients who progressed on VEGF-targeted therapy. This evidence concerns the gene TSC2 and renal cell carcinoma.